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Background: Previous research in animal seizure models indicates that the pleiotropic cytokine TNF is an important
effector/mediator of neuroinflammation and cell death. Recently, it has been demonstrated that TNF downregulates
Klotho (KL) through the nuclear factor kappa B (NFkB) system in animal models of chronic kidney disease and
colitis. KL function in the brain is unclear, although Klotho knockout (Kl−/−) mice exhibit neural degeneration and a
reduction of hippocampal synapses. Our aim was to verify if the triad KL-NFKB1-TNF is also dysregulated in temporal
lobe epilepsy associated with hippocampal sclerosis (TLE(HS)) patients.
Findings: We evaluated TNF, NFKB1 and KL relative mRNA expression levels by reverse transcription quantitative
PCR (RT-qPCR) in resected hippocampal tissue samples from 14 TLE(HS) patients and compared them to five post
mortem controls. Four reference genes were used: GAPDH, HPRT1, ENO2 and TBP. We found that TNF expression was
dramatically upregulated in TLE(HS) patients (P <0.005). NFKB1 expression was also increased (P <0.03) while KL was
significantly downregulated (P <0.03) in TLE(HS) patients. Hippocampal KL expression had an inverse correlation
with NFKB1 and TNF.
Conclusions: Our data suggest that, similar to other inflammatory diseases, TNF downregulates KL through NFkB in
TLE(HS) patients. The remarkable TNF upregulation in patients is a strong indication of hippocampal chronic
inflammation. Our finding of hippocampal KL downregulation has wide implications not only for TLE(HS) but also
for other neuronal disorders related to neurodegeneration associated with inflammation.
Keywords: Seizures, Hippocampal sclerosis, Neuroinflammation, TNF, KL, NFKB1, GFAP, Reference genes, Calcium
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Introduction
Temporal lobe epilepsy (TLE) is the most treatment re-
sistant (refractory) partial epilepsy and only 20% of pa-
tients achieve seizure control with antiepileptic drugs
(AEDs) [1]. Hippocampal sclerosis (HS) is the main
pathological finding observed in excised tissue from TLE
patients treated with amygdalohippocampectomy. Only
10% of TLE patients with HS, who are treated with
AEDs, become seizure-free which emphasizes the* Correspondence: ldesouza@fcm.unicamp.br
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reproduction in any medium, provided the orimportance of HS as a prognostic factor [1]. HS is char-
acterized by an abnormal increase in the number of as-
trocytes associated with the destruction of nearby
neurons (astrogliosis) [2]. One of the primary events in
seizure-induced cell death in the hippocampus is the ex-
cessive release of glutamate with consequent overload in
intracellular calcium influx [3]. Within the neuronal
cells, sophisticated homeostatic mechanisms control cal-
cium levels. Altered Ca2+ sensitivity or defective Ca2+
regulation appear to be involved in the aging process,
contributing to the progressive neurodegeneration in
Alzheimer’s disease and the intensified susceptibility to
cell death after a seizure or stroke [3,4].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tein, is involved in multiple functions in many systems
and acts as an important calciophosphoregulatory hor-
mone [5]. KL mRNA is expressed only in limited organs,
that is the brain, kidney, reproductive organs, pituitary
gland and parathyroid glands [6,7]. Its cerebral function
is unclear, however Klotho knockout (Kl−/−) mice exhibit
a phenotype resembling human aging, showing neural
degeneration and a reduction of synapses in the hippo-
campus [6]. In addition, KL regulates the cellular life-
span of human cells by repressing the pro-apoptotic
tumor protein p53 (TP53) [8], which regulates a number
of apoptosis-related genes.
Important components and features of medial TLE,
such as hippocampal intracellular calcium imbalance,
neurodegeneration, hippocampal atrophy and cognitive
decline, led us to question whether KL would also be
downregulated in temporal lobe epilepsy associated with
hippocampal sclerosis (TLE(HS)) patients. Furthermore,
several studies assert that inflammation has a crucial role
in epileptogenesis [9] and an increasing body of evidence
connects astrogliosis to neuroinflammation [10]. In epi-
lepsy, the pleiotropic cytokine TNF is indicated as being
an important effector/mediator of neuroinflammation and
cell death [9,11-15]. Interestingly, it has been demon-
strated that TNF downregulates KL through the transcrip-
tion nuclear factor kappa B (NFkB) in animal models of
chronic kidney disease and colitis [16,17]. Since inflamma-
tion and neurodegeneration seem to be connected in HS,
our objective was to verify if the triad KL-NFKB1-TNF is
also dysregulated in TLE(HS).Table 1 Clinical and demographic features of TLE(HS) patient
Patients Gender Age (years) Side of HS Duration (years) L
TLE 01 F 34.6 L 28.6
TLE 02 F 29.1 L 22.1
TLE 03 F 23.8 R 22.3
TLE 04 M 42.8 R 41.2
TLE 05 M 41.2 L 34.2
TLE 06 M 50.8 R 48.8
TLE 07 M 12.7 L 9.7
TLE 08 F 43.8 B(L)a 41.8
TLE 09 F 58.2 R 57.7
TLE 10 F 54.9 L 50.9
TLE 11 F 32.1 L 31.6
TLE 12 F 38.3 L 37.0
TLE 13 F 54.1 L 53.3
TLE 14 M 34.4 R 34.2
aThe hippocampal side was more affected when bilateral. When the patient’s last se
TLE(HS), temporal lobe epilepsy associated with hippocampal sclerosis; M, male; F, f
CBZ, carbamazepine; PHT, phenytoin; OXC, oxcarbazepine; LTG, lamotrigine; VPA, vaMethods
Ethical approval was certified by the “Comitê de Ética da
Faculdade de Ciências Médicas da Unicamp (CEP n 470/
2003)”.
Patients, post mortem controls and tissues
Electroencephalogram (EEG) video monitoring/telem-
etry was performed on all patients to confirm the onset
of seizure in the medial temporal lobe. Dual pathologies
or multifocal epilepsies were not identified. Hippocam-
pal atrophy was detected by magnetic resonance imaging
(MRI) in all patients.
Each patient signed an informed consent agreement to
allow scientific use of the tissue. All procedures were
carried out with the approval of the local research ethics
committee, and in compliance with institutional guide-
lines and relevant laws.
Fourteen TLE(HS) patients had the amygdalohippo-
campectomy procedure performed for therapeutic reasons
(Table 1). Hippocampal tissue samples from all 14 patients
were immediately collected and divided into two parts. One
portion was immediately snap-frozen in liquid nitrogen and
stored at −80°C until RNA isolation occurred. The second
portion was fixed for histopathological analysis and HS was
confirmed in all of them.
Five post mortem control hippocampal tissue samples
(one female, four males; 28.2 ± 13.1 years; range from 19
to 50 years old) were provided by the Instituto Médico
Legal (IML) de Campinas. Despite some traumatic deaths,
no neurological abnormalities were detected. Subjects
passed away unexpectedly and instantly, which minimizess







3 Sporadic CBZ, PHT
nd Sporadic CBZ, LTG




nd Sporadic OXC, PHT
nd Familial OXC
izure was ‘nd’, the seizure most likely occurred over 7 days prior to surgery.
emale; B, bilateral; R, right; L, left; nd, not determined; AED, antiepileptic drug;
lproate.
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The post mortem delay averaged 7.8 hours (range from 6
to 9 hours).
RNA extraction and reverse transcription quantitative PCR
(RT-qPCR)
To extract total RNA, 1 ml of TRIzol Reagent (Life
Technologies, Foster City, CA, USA) was added per 75
mg of frozen tissue samples, homogenized and then fur-
ther processed according to the manufacturer’s instruc-
tions. The RNA integrity number (RIN) mean in both
the control and patient groups was similar: 6.68 ±
0.9441 (n = 5) and 6.155 ± 0.2484 (n = 11), respectively.
Due to the fact that the RNA was unavailable, the RIN
was not evaluated for three patient samples: TLE 03,
TLE 11 and TLE 13. Subsequently, 1 μg of total RNA of
each sample was reverse transcribed into cDNA using
200 U of Superscript III Reverse Transcriptase (Life
Technologies) and 3 μg of Random Primers (Life Tech-
nologies) according to the manufacturer’s instructions.
Sterilized and filtered DEPC-treated water was used in
all cDNA synthesis reactions. Complementary DNA
samples derived from the investigated genes were
detected using an ABI PRISM 7500 Sequence Detection
System (Life Technologies) and TaqMan Gene Expres-
sion Assays (Life Technologies): 5′-FAM-labeled probes
and corresponding primer pairs (Table 2). Gene names
are in accordance with the approved symbol from the
HUGO Gene Nomenclature Committee (HGNC) data-
base. To select the reference genes (endogenous con-
trols), the study of Wierschke et al. on human
epileptogenic tissues was considered [18]. Among 12
candidate genes, the algorithm NormFinder indicated
hypoxanthine phosphoribosyltransferase 1 (HPRT1),
enolase 2 (gamma, neuronal) (ENO2) and TATA box
binding protein (TBP) as good normalization factors,
since as single genes their expression levels were among
the five most stable. Glyceraldehyde-3-phosphate de-




ENO2 Enolase 2 (gamma, neuronal) Refere
GAPDH Glyceraldehyde-3-phosphate dehydrogenase Refere
GFAP Glial fibrillary acidic protein Upre
m
HPRT1 Hypoxanthine phosphoribosyltransferase 1 Refere
KL Klotho Ta
NFKB1 Nuclear factor of kappa light polypeptide gene
enhancer in B-cells 1
Ta
TBP TATA box binding protein Refere
TNF Tumor necrosis factor Tashowed a relatively unstable expression. However, to
reinforce our results, we opted to test all four reference
genes. Glial fibrillary acidic protein (GFAP) was used as
an upregulation control [18-20]. Each qPCR was run as
triplicates with 10 ng cDNA sample in 6.25 μl TaqMan
Gene Expression Master Mix (Life Technologies), 0.625
μl of the respective probe/primer mix, and 0.625 μl puri-
fied and deionized H2O.
The amplification of all samples was of the same effi-
ciency for precise quantification of reverse transcription
quantitative PCR (RT-qPCR) data. Serial fivefold dilu-
tions, starting with 250 ng of cDNA from the RNA
quantification, of a cDNA solution pooled from the con-
trol group was used. The mean CT values, measured in
triplicates, versus the log10 of the dilution was plotted.
The values from linear regressions applied to these plots
were also presented (not shown). The amplification effi-
ciencies (E = 10(−1/slope)) were close to 1.0 (100%).Data analysis
Relative gene expression quantification data was gener-
ated and analyzed using the 7500 Software version 2.0.5
(Life Technologies). One of the post mortem control
samples was randomly chosen as the benchmark and the
quantification data from the other samples, including
controls and patients, was evaluated according to this
reference sample, which always had a relative quantifica-
tion of 1.0. This allowed the two groups (post mortem
controls and TLE(HS) patients) to be statistically
compared.
The GraphPad Prism 5 software version 5.04 for Win-
dows was used for the statistical analysis (San Diego,
CA, USA; www.graphpad.com). The Mann–Whitney U
test was used for comparison between data from the
control group (n = 5) versus the patient group (n = 14).
All comparison data are presented as mean and SD. Cor-
relation among the target genes was performed by the






nce gene Hs00157360_m1 77 −3.356 0.994 98.61
nce gene 4333764 F 122 −3.313 0.996 100.36
gulation
arker
Hs00909236_m1 59 −3.414 0.999 96.29
nce gene 4333768 F 100 −3.306 0.988 100.67
rget Hs00183100_m1 74 −3.396 0.998 97.02
rget Hs00765730_m1 66 −3.388 0.997 97.30
nce gene Hs99999910_m1 127 −3.407 0.993 96.57
rget Hs99999043_m1 85 −3.266 0.991 102.39
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and differences of P <0.05 were considered significant.
Results and discussion
The quality of the RNA and the reliability of reference
genes to quantify gene expression in surgical tissue are
crucial in interpreting epilepsy-related changes of gene
expression [18,21]. The similarity in the RIN average be-
tween TLE patients and the control group (6.68 ±
0.9441 and 6.155 ± 0.2484, respectively) reinforces our
results. Post mortem delay has always been considered a
major factor when interpreting the accuracy of results
from human tissue studies; however, this may not be a
factor for human brain RNA [21]. Durrenberger et al.
concluded that post mortem delay caused only a minor
deterioration and had no effect on RNA quality. The
same results were found in previous research mentioned
in their report [21]. We worked with a post mortem
delay of between 6 to 9 hours, which would not seem to
contradict the findings of the Durrenberger study.
Our results (Figure 1) showed a dramatic increase on
TNF relative mRNA expression in hippocampal tissue of
TLE(HS) patients in comparison with the post mortem
controls (P <0.005, regardless of the reference gene).
Despite the same P value for the results regarding the
four reference genes used, the TNF expression mean inFigure 1 Hippocampal relative gene expression of KL, NFKB1, TNF and
control group. Different colors represent the four reference genes used: G
target genes (KL, NFKB1 and TNF) and the upregulation marker (GFAP), four
was considered as an independent variable. The y-axis represents the quan
in sclerotic hippocampal tissues of the TLE(HS) patient group (n = 14) com
presented as mean and SD. Mann–Whitney U tests were used for comparis
epilepsy associated with hippocampal sclerosis.patients had an ample variation: from 29.61 ± 8.55
(TBP) to 110.4 ± 58.82 (HPRT1). The combination of
ENO2 and TBP as the normalization factor proved to be
very stable in epileptogenic tissues [18]. Therefore, in
Figure 2, we used this combination to show the relative
TNF expression individually by subject.
Our data suggests that the marked TNF upregulation in
patients’ tissues corroborates with the chronic hippocam-
pal inflammation in TLE(HS). Table 1 shows that several
patients had their last seizure several days before the sur-
gery, suggesting that the high TNF expression levels were
frequent, signaling that chronic hippocampal inflammation
could be intrinsic to the refractory TLE(HS) syndrome. A
number of studies in animal models indicate that seizures
induce TNF expression in the brain [9,11-14]. Our findings
confirm that a similar induction also occurs in TLE pa-
tients. However, despite the intense investigation of the
TNF system and its effects in seizure models, there is not
unanimous agreement on its effects in TLE(HS) and clin-
ical studies are scarce [11]. Moreover, similar to recent
findings on inflammatory disease models [16,17], our data
indicates that the synthesis of KL is reduced in the sclerotic
hippocampus and TNF may downregulate KL through
NFkB in TLE(HS) (Figures 1 and 2).
While KL mRNA was significantly downregulated
(HPRT1 and TBP: P <0.001; GAPDH: P <0.02; ENO2: PGFAP in the TLE(HS) patient group versus the post mortem
APDH (red), HPRT1 (yellow), ENO2 (green) and TBP (blue). For the three
independent comparisons were performed, since each reference gene
titative data of the relative mRNA expression of the target molecules
pared with the post mortem control group (n = 5). All data are
ons between groups. *P <0.05, **P <0.01. TLE(HS), temporal lobe
Figure 2 Dispersion of the relative gene expression of KL and TNF in the hippocampus of TLE(HS) patients and post mortem controls.
The y-axis represents the quantitative data of the relative mRNA expression of KL and TNF. The x-axis corresponds to the two groups: post
mortem controls (n = 5, circles) and TLE(HS) patients (n = 14, squares and triangles). In the control group, the unfilled circle represents the
calibrator sample, whose gene expression is always 1.0. The combination of ENO2 and TBP was used as the reference gene. Mann–Whitney U
tests were used for comparison between groups. TLE(HS), temporal lobe epilepsy associated with hippocampal sclerosis.
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mented in patients (GAPDH, HPRT1 and ENO2: P
<0.02; TBP: P <0.03) (Figure 1). It remains to be eluci-
dated whether the KL depressed expression has a role in
TLE(HS) physiopathology or is only a secondary change
caused by the imbalance of calcium or phosphate and/or
the progression of HS in the medial TLE syndrome.
Since KL is a pleiotropic protein with different functions
on many systems, our findings on KL downregulation
opens up a gamut of study possibilities in HS patho-
physiology comprehension.
We initially highlighted two specific functions assigned
to KL: it has a stimulating effect on the Na+/K+ ATPase
pump activity [22] and it influences the Wnt signal path-
way [23]. Considering the importance of Na+/K+ ATPase
activity in neuronal electrical activity and excitability
[24], it is important to determine if KL regulates Na+/K+
ATPase in the hippocampus, which could be involved
with the evident synaptic reduction found in Kl−/− mice
[6,7]. The molecular mechanisms regarding the neurode-
generative feature found in Kl−/− mice and analogously
to HS have not yet been elucidated. By acting on the
Wnt signaling, KL offers an interesting outlook as it sup-
presses several Wnt family members [23]. It has been
demonstrated that stimulation of Wnt signaling contrib-
utes to stem and progenitor cell senescence, and persist-
ent decreased KL expression may affect the rate of
cellular aging and have harmful impact on tissue repair
mechanisms [17]. This could be a key factor in HS
progression.
There is another connection between KL depression
and astrogliosis. By suppressing TP53 and nega-
tively regulating cyclin-dependent kinase inhibitor 1
(CDKN1A, also known as p21) protein levels, KL not
only inhibits apoptosis but also modulates the lifespan of
human cells, which may be associated with increased
signaling through the insulin/insulin-like growth factor 1
(IGF-1) pathway [8]. This growth factor has a significantrole in non-neuronal modulation and multiple reports
have indicated that astrocytes are the main target of
IGF-1 by regulating their response to tissue injury [25].
Since KL may inhibit the insulin/IGF-1 pathway [26], its
downregulation could support astrogliosis by a detri-
mental effect on neurons and astrocyte proliferation. In
fact, Kl−/− mice have neuronal cell degeneration with a
drastic increase in GFAP levels [27]. As expected,
GFAP was upregulated in patients (GAPDH, HPRT1
and ENO2: P <0.001; TBP: P <0.02), which supports
astrogliosis (Figure 1).
Furthermore, KL has been considered an anti-
inflammatory protein and this property could be one of
its most striking features. In the endothelium, KL con-
fers protection against nitric oxide (NO)-induced dys-
function [28], reduces the expression of adhesion
molecules [28] and potentially regulates T cell functions
[29]. In 2007, Witkowski et al. reported that KL was
downregulated in CD4+ lymphocytes at the mRNA, pro-
tein and enzymatic (beta-glucoronidase) activity levels in
healthy, older adults and especially in rheumatoid arth-
ritis (RA) patients [29]. Regardless of the unclear link
between KL activity and CD4+ cell function, they pro-
posed that KL might be involved in physiological anti-
inflammatory responses in young individuals, but these
responses decreased in both healthy older adults and RA
patients. Their hypothesis was supported by the fact that
KL expression and activity reduction, in both older
adults and RA patients’ lymphocytes, occurred in con-
cert with the downregulation of CD28, a TNF-increased
dependent T cell costimulatory molecule.
The Kl−/− mouse also exhibits atherosclerosis and
endothelial dysfunction, which led Maekawa et al. [28]
to test the effect of KL on vascular inflammation. KL
suppressed the TNF-induced expression of adhesion
molecules and NFkB activation in endothelial cells
in vitro (human umbilical vein endothelial cells
(HUVECs)) and ex vivo (organ culture of the rat aorta).
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synthase 3 (NOS3) phosphorylation by TNF and
inhibited the TNF-induced monocyte adhesion to
HUVECs. These results suggest that KL may have a
function in the modulation of endothelial inflammation,
especially by TNF-induced NFkB inhibition. Therefore,
it is plausible that KL downregulation could further ex-
acerbate the TLE(HS) associated chronic inflammatory
condition.
Moreno et al. related that the inflammatory cytokines
tumor necrosis factor ligand superfamily member 12
(TNFSF12, also known as TWEAK) and TNF
downregulate KL in renal tubular cells through an
NFkB-dependent mechanism mediated by histone
deacetilase 1 (HDAC1) [16]. In this regard, they ob-
served that the HDAC inhibitors trichostatin A (TSA) or
valproic acid prevented repression of KL induced by
TWEAK or TNF. Among the patients studied, only TLE
09 was taking valproate during the surgery and only
TLE 06 took this medication in the past. We did not ob-
serve any particular difference in these patients com-
pared with the others. KL expression was negatively
correlated with NFBK1 or TNF expression, while the
pair TNF and NFKB1 showed a positive correlation. This
suggests that NFkB in patients is most likely modulated
by TNF or even KL [28] and not by AEDs, although fur-
ther studies are required to test the influence of AEDs in
the gene expression of our targets. Gene expression data
correlation was found in the three pairs tested: KL-
NFKB1 (Spearman’s R = −0.3140; P = 0.0091), KL-TNF
(Spearman’s R = −0.3283; P = 0.0063), and NFKB1-TNF
(Spearman’s R = 0.4441; P = 0.0001).
In addition, Thurston et al. showed that in mouse
models of inflammatory bowel disease the degree of KL
inhibition was related to the severity of colitis and that
attenuation of inflammation with a neutralizing anti-
TNF antibody impeded this inhibition [17]. Furthermore,
the neurodegenerative feature found in Kl−/− mice sug-
gests that KL in the hippocampus may act as a protect-
ive autocrine hormone and its absence causes neuronal
loss [30].
Our work on the mRNA level suggests that the triad
KL-NFKB1-TNF is disrupted in the hippocampus from
medically intractable TLE patients. Based on the KL
function studies discussed here, we propose the first
mechanistic insights into the role that this triad may
play in the pathogenesis of medial TLE. It is conceivable
that there is a major involvement of the KL-TNF axis in
the pathogenesis of TLE(HS), particularly under chronic
inflammatory conditions. Further research on the pro-
tein level will strengthen our results and the design of
functional studies will be able to elucidate the role of
our targets, especially KL, in the normal and patho-
logical hippocampus. Due to the KL hormonal property[7,31] and TNF tissue diffusion as a cytokine [32,33], we
believe that the epilepsy-associated inflammation is a
widespread event in the hippocampus. Finally, since KL
is detectable in cerebrospinal fluid [7,31,34], it is a po-
tential candidate as an inflammatory biomarker in epi-
lepsy. The inflammatory component of epilepsy is not a
secondary phenomenon or complication of the path-
ology. It is more likely involved in the mechanisms that
sustain neuronal hyperexcitability, the onset and recur-
rence of seizures, and progression and severity of the
disease [15]. The determination of a reliable biomarker
of brain inflammation is urgent, in view of the fact that
a number of patients would benefit from an anti-
inflammatory therapy.
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